表紙
市場調査レポート

抗体医薬品:技術および世界市場

Antibody Drugs: Technologies and Global Markets

発行 BCC Research 商品コード 230632
出版日 ページ情報 英文 141 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
抗体医薬品:技術および世界市場 Antibody Drugs: Technologies and Global Markets
出版日: 2015年01月01日 ページ情報: 英文 141 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

当レポートでは、抗体医薬品の世界市場に注目し、各種抗体薬分野の成長性を質・量の両面から評価すべく、今後の方向性と発展規模を展望するほか、技術的諸問題や競合企業・製品についての最新分析情報をまとめてお届けします。

第1章 イントロダクション - はじめに

  • 調査の最終目標と中間指標
  • 調査の背景
  • 対象読者
  • レポートの範囲
  • 情報源
  • アナリストについて
  • 関連レポート
  • BCCオンラインサービス
  • 免責事項

第2章 サマリー

  • サマリー表:世界の抗体治療薬市場(地域別)
  • サマリー図:世界の抗体治療薬市場(地域別)

第3章 概要

  • 定義
  • 単クローン抗体医薬品
    • 単クローン抗体医薬品の歴史
    • 単クローン抗体医薬品の種類
    • 単クローン抗体医薬品の製造技術
    • 単クローン抗体医薬品の利用

第4章 規制面

  • リコール
  • 新薬の申請/生物学的製剤承認
  • 安全警報

第5章 開発

  • 第?相治験
  • 第?相治験
  • 第?相治験
  • 第?相治験
  • M&A

第6章 市場分析

  • タイプ別
  • 地域別
  • 製造工程別

第7章 用途

  • 疾患別市場
  • 世界の抗体医薬品市場;疾患別
    • 市場シェア
    • 自己免疫疾患
    • 固形腫瘍
    • リンパ腫および白血病
    • その他

第8章 産業構造

  • マウス単クローン抗体
    • 業界リーダー
    • 市場シェア
  • キメラ化単クローン抗体
  • ヒト化単クローン抗体
  • ヒト単クローン抗体

第9章 特許分析

  • 年別特許件数
  • 種類/カテゴリー別
  • 企業別
  • 国別
  • 譲受人別

第10章 現状

  • 技術・技法の問題点
    • HAMA(ヒトの抗マウス抗体)問題
    • ヒト化、キメラ化、遺伝子組み換え抗体の優位点
  • 開発中の抗体技術
  • 治療法に応じたその他の抗体の優位点
  • 単クローン抗体医薬品市場への影響因子

第11章 企業プロフィール

  • ABBOTT LABORATORIES
  • ALEXION PHARMACEUTICALS
  • AMGEN
  • BIOGEN IDEC
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND CO.
  • GLAXOSMITHKLINE
  • HOFFMAN-LA ROCHE
  • JOHNSON & JOHNSON
  • MERCK & CO.
  • MERCK KGAA
  • NOVARTIS
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS
  • TAKEDA PHARMACEUTICAL U.S.A. INC.
  • UCB COMPANY

第12章 付録:略語一覧

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO016J

The global market for antibody drugs was worth nearly $63.4 billion in 2013. This market is expected to grow at a compound annual growth rate (CAGR) of 12.2% between 2014 and 2019 resulting in totals nearly $68.9 billion in 2014 and $122.6 billion globally in 2019.

This report provides:

  • An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
  • Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
  • Analysis and assessment of the therapeutic applications of mAbs in human medicine.
  • A look at the antibody industry as a whole as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
  • Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

image1

REPORT SCOPE

SCOPE OF THE STUDY

The scope of this report embraces the key market analysis, market drivers, market constraints, and also competitive developments and trends in this market. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections and market shares. The study involves the antibody drugs used in the pharmaceutical and the biopharmaceutical markets. This report analyzes and assesses therapeutic applications of mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agent such as with antibody-drug conjugates (ADCs).

Excluded from this report is information regarding polyclonal antibodies, as well as screening equipment and diagnostic uses (such as for imaging purposes) of mAbs. Also excluded is discussion relating to the research applications of mAbs and therapeutic antibodies for veterinary use. Complete geographical analysis of market is also studied in report. The emerging market for mAbs includes countries such as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth. Profiles of key market players are also covered for this report. The U.S. and Europe markets are also covered.

The technological issues include all the latest trends, for example, the human antimouse antibody (HAMA) problem because of murine antibodies and its resolution by using chimeric, human and humanized antibodies instead of murine antibodies for therapy, pipeline products and developments. Also included in the report are comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development (R&D) of antibody drugs.

ANALYST'S CREDENTIALS

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a Master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest such as ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC Research are:

  • Reagents of Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems.
  • Orthopedic Drugs, Implants and Devices.
  • Imaging Reagents; Regulatory Industry.
  • Dynamic Sera, Media and Reagents Used in Biotechnology.
  • Contract Pharmaceutical Manufacturing, Research and Packaging.
  • Chiral Technology: Global Markets.
  • Autacoids and Related Drugs.
  • Contraceptives.
  • Liver Disease Treatments.
  • The Global Market, Hormone Replacement Therapies and Other Hormone Therapies.
  • Global Markets (PHM055A); Cardiovascular Medicine: Diagnostics, Drugs and Devices.
  • Cancer Therapies: Technologies and Global Market.
  • Medical Imaging Reagents and Analysis Equipment.

The lead analysts for this project were Honey Dave and Lakshmi Prasanna. Both analysts hold a Master's degree in biotechnology. They have written many research publications, and their interests include proteomics, genomics, pharmacology and gene sequencing.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, 2012-2019 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • DEFINITIONS
  • MONOCLONAL ANTIBODIES
    • HISTORY OF MONOCLONAL ANTIBODIES
    • TABLE 1 EVOLUTION OF MONOCLONAL ANTIBODIES
    • TABLE 2 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
    • TABLE 3 DIFFERENCES BETWEEN MONOCLONAL ANTIBODY DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
    • TYPES OF MONOCLONAL ANTIBODIES
      • Murine Monoclonal Antibodies
      • TABLE 4 MURINE MONOCLONAL ANTIBODIES
      • Chimeric Monoclonal Antibodies
      • TABLE 5 CHIMERIC MONOCLONAL ANTIBODIES
      • Humanized Monoclonal Antibodies
      • TABLE 6 HUMANIZED MONOCLONAL ANTIBODIES
      • Human Monoclonal Antibodies
      • TABLE 7 HUMAN MONOCLONAL ANTIBODIES
    • MANUFACTURING TECHNOLOGIES OF MONOCLONAL ANTIBODIES
      • Hybridoma Technology
      • Production of Recombinant Antibodies by Display Technology
      • TABLE 8 DIFFERENCES BETWEEN HYBRIDOMA TECHNOLOGY AND RECOMBINANT TECHNOLOGY
      • Production of Antibodies in Plants
      • Recombinant Antibody Expression in Transgenic Plants
      • Recombinant Antibody Expression in Transgenic Animals
      • Mammalian Cell Culture
      • Microbial Cell Fermentation
      • TABLE 9 COMPARISON OF VARIOUS EXPRESSION SYSTEMS FOR RECOMBINANT PHARMACEUTICAL PROTEINS
    • APPLICATIONS OF MONOCLONAL ANTIBODIES
      • Diagnostic Tests
      • Human Therapy
      • TABLE 10 MURINE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
      • TABLE 11 CHIMERIC MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
      • TABLE 12 HUMAN MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
      • TABLE 13 HUMANIZED MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS

CHAPTER 4 REGULATORY ASPECTS

  • TABLE 14 NEW APPROVALS OF MONOCLONAL ANTIBODIES FROM JANUARY 2009 TO MAY 2014
  • RECALLS
  • TABLE 15 RECALLS FROM JANUARY 2009 TO JUNE 2014
  • NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS
  • TABLE 16 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS FROM JANUARY 2009 TO JANUARY 2014
  • SAFETY ALERTS
  • TABLE 17 SAFETY ALERTS FROM 2010 TO MAY 2014

CHAPTER 5 NEW DEVELOPMENTS

  • PHASE I CLINICAL TRIALS
  • TABLE 18 MONOCLONAL ANTIBODIES IN PHASE I CLINICAL TRIALS
  • PHASE II CLINICAL TRIALS
  • TABLE 19 MONOCLONAL ANTIBODIES IN PHASE II CLINICAL TRIALS
  • PHASE III CLINICAL TRIALS
  • TABLE 20 MONOCLONAL ANTIBODIES IN PHASE III CLINICAL TRIALS
  • PHASE IV CLINICAL TRIALS
  • TABLE 21 MONOCLONAL ANTIBODIES IN PHASE IV CLINICAL TRIALS
  • MERGERS AND ACQUISITIONS
  • TABLE 22 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES FROM 2009 TO JUNE 2014

CHAPTER 6 MARKET ANALYSIS OF ANTIBODY DRUGS

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 23 GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 1 GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, 2012-2019 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 24 MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013 (%)
    • FIGURE 2 MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013 (%)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 25 GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 3 GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, 2012-2019 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 26 MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013 (%)
    • FIGURE 4 MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013 (%)
      • Murine Monoclonal Antibodies
        • Market Overview
        • Market Revenue
        • TABLE 27 GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 5 GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
      • Chimeric Monoclonal Antibodies
        • Market Overview
        • Market Revenue
        • TABLE 28 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 6 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
      • Human Monoclonal Antibodies
        • Market Overview
        • Market Revenue
        • TABLE 29 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 7 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
      • Humanized Monoclonal Antibodies
        • Market Overview
        • Market Revenue
        • TABLE 30 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 8 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
  • MARKET BY MANUFACTURING PROCESS
  • TABLE 31 GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, THROUGH 2019 ($ MILLIONS)
  • FIGURE 9 GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, 2012-2019 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 32 MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013 (%)
    • FIGURE 10 MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013 (%)
      • Murine Monoclonal Antibodies
        • Market Overview
        • Market Revenue
        • TABLE 33 GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 11 GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2012-2019 ($ MILLIONS)
      • Chimeric Monoclonal Antibodies
        • Market Overview
        • Market Revenue
        • TABLE 34 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 12 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 ($ MILLIONS)
      • Human Monoclonal Antibodies
        • Market Overview
        • Market Revenue
        • TABLE 35 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 13 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 ($ MILLIONS)
      • Humanized Monoclonal Antibodies
        • Market Overview
        • Market Revenue
        • TABLE 36 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 ($ MILLIONS)
        • FIGURE 14 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 ($ MILLIONS)

CHAPTER 7 MARKET APPLICATIONS OF ANTIBODY DRUGS

  • MARKET BY DISEASES
  • GLOBAL ANTIBODY DRUG MARKET BY DISEASES
  • TABLE 37 GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, THROUGH 2019 ($ MILLIONS)
  • FIGURE 15 GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, 2012-2019 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 38 MARKET SHARES FOR ANTIBODY DRUGS BY DISEASES, 2013 (%)
    • FIGURE 16 MARKET SHARE FOR ANTIBODY DRUGS BY DISEASES, 2013 (%)
    • AUTOIMMUNE DISEASE
    • TABLE 39 VARIOUS TYPES OF AUTOIMMUNE DISEASES
      • Autoimmune Diseases by Type of Antibody Used
        • Market Overview
        • Market Revenue
        • TABLE 40 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, THROUGH 2019 ($ MILLIONS)
        • FIGURE 17 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, 2012-2019 ($ MILLIONS)
      • Market Analysis of Autoimmune Diseases by Region
        • Market Overview
        • Market Revenue
        • TABLE 41 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 18 GLOBAL MARKET FOR ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, 2012-2019 ($ MILLIONS)
        • SOLID TUMORS
        • TABLE 42 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN
      • Market Analysis of Solid Tumors by Type of Antibody Used in Treatment
        • Market Overview
        • Market Revenue
        • TABLE 43 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, THROUGH 2019 ($ MILLIONS)
        • FIGURE 19 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, 2012-2019 ($ MILLIONS)
      • Market Analysis of Solid Tumors by Region
        • Market Overview
        • Market Revenue
        • TABLE 44 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 20 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, 2012-2019 ($ MILLIONS)
    • LYMPHOMAS AND LEUKEMIA
      • Lymphoma
      • TABLE 45 TYPES OF LYMPHOMAS
      • Leukemia
      • TABLE 46 TYPES OF LEUKEMIA
      • Market Analysis of Lymphomas and Leukemia by Type of Antibody Used in Treatment
        • Market Overview
        • Market Revenue
        • TABLE 47 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, THROUGH 2019 ($ MILLIONS)
        • FIGURE 21 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, 2012-2019 ($ MILLIONS)
      • Market Analysis of Lymphomas and Leukemia by Region
        • Market Overview
        • Market Revenue
        • TABLE 48 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 22 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, 2012-2019 ($ MILLIONS)
    • OTHERS
      • Osteoporosis
      • Asthma
      • Age-related Macular Degeneration
      • Paroxysmal Nocturnal Hemoglobinuria
      • Cardiovascular Diseases
      • Respiratory Syncytial Virus Infection
      • Market Analysis of Other Diseases by Type of Antibody Used in Treatment
        • Market Overview
        • Market Revenue
        • TABLE 49 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY TYPE, THROUGH 2019 ($ MILLIONS)
        • FIGURE 23 GLOBAL REVENUE OF ANTIBODY DRUGS BY APPLICATION IN OTHER DISEASES BY TYPE, 2012-2019 ($ MILLIONS)
      • Market Analysis of Other Diseases by Region
        • Market Overview
        • Market Revenue
        • TABLE 50 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
        • FIGURE 24 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, 2012-2019 ($ MILLIONS)

CHAPTER 8 INDUSTRY STRUCTURE

  • MURINE MONOCLONAL ANTIBODIES
    • MARKET LEADERS
    • TABLE 51 LEADING MANUFACTURERS/SUPPLIERS OF MURINE MONOCLONAL ANTIBODIES, 2013
    • MARKET SHARE
    • TABLE 52 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013 (%)
    • FIGURE 25 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013 (%)
  • CHIMERIC MONOCLONAL ANTIBODIES
    • MARKET LEADERS
    • TABLE 53 LEADING MANUFACTURERS/SUPPLIERS OF CHIMERIC MONOCLONAL ANTIBODIES, 2013
    • MARKET SHARE
    • TABLE 54 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013 (%)
    • FIGURE 26 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013 (%)
  • HUMANIZED MONOCLONAL ANTIBODIES
    • MARKET LEADERS
    • TABLE 55 LEADING MANUFACTURERS/SUPPLIERS OF HUMANIZED MONOCLONAL ANTIBODIES, 2013
    • MARKET SHARE
    • TABLE 56 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013 (%)
    • FIGURE 27 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013 (%)
  • HUMAN MONOCLONAL ANTIBODIES
    • MARKET LEADERS
    • TABLE 57 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN MONOCLONAL ANTIBODIES, 2013
    • MARKET SHARE
    • TABLE 58 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013 (%)
    • FIGURE 28 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013 (%)

CHAPTER 9 PATENT ANALYSIS

  • PATENTS BY YEAR
  • TABLE 59 NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014
  • FIGURE 29 NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014
  • PATENTS BY TYPE/CATEGORY
  • TABLE 60 NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014
  • FIGURE 30 NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014
  • PATENTS BY COMPANY
  • TABLE 61 NUMBER OF PATENTS BY COMPANY, 2009-JUNE 2014
  • PATENTS BY COUNTRY
  • TABLE 62 NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014
  • TABLE 63 PATENT SHARES BY COUNTRY, 2009-JUNE 2014
  • FIGURE 31 NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014 (%) (%)
  • PATENTS BY ASSIGNEE
  • TABLE 64 NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014
  • FIGURE 32 NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014

CHAPTER 10 CURRENT SITUATION

  • TECHNICAL ISSUES
    • THE HUMAN ANTIMOUSE ANTIBODY PROBLEM
      • Effects of the HAMA Response
      • Resolution of the HAMA Problem
    • ADVANTAGES OF HUMANIZED OR CHIMERIC OR TRANSGENIC ANTIBODIES
  • NEW TECHNOLOGIES IN ANTIBODY DEVELOPMENT
    • FUSION PROTEINS
    • AFFIBODIES
    • NANOBODIES
    • TABLE 65 NANOBODIES IN DEVELOPMENT
  • OTHER ADVANCES IN ANTIBODIES DEPENDING ON THE TREATMENT
  • FACTORS AFFECTING THE MONOCLONAL ANTIBODY DRUG MARKET
    • INCREASING PREVALENCE OF CHRONIC DISEASES
    • GROWING AGING POPULATION
    • LIFESTYLE CHANGES
    • NEW PRODUCT LAUNCHES
    • ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES
    • PRICE CONTROLS
    • REGULATORY PRESSURES
    • ENTRY OF BIOLOGICS/BIOSIMILARS
    • LICENSING AGREEMENTS
    • MERGERS AND ACQUISITIONS

CHAPTER 11 COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ALEXION PHARMACEUTICALS
  • AMGEN
  • BIOGEN IDEC
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND CO.
  • GLAXOSMITHKLINE
  • HOFFMAN-LA ROCHE
  • JOHNSON & JOHNSON
  • MERCK & CO.
  • MERCK KGAA
  • NOVARTIS
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS
  • TAKEDA PHARMACEUTICAL U.S.A. INC.
  • UCB COMPANY

CHAPTER 12 APPENDIX ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 EVOLUTION OF MONOCLONAL ANTIBODIES
  • TABLE 2 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
  • TABLE 3 DIFFERENCES BETWEEN MONOCLONAL ANTIBODY DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
  • TABLE 4 MURINE MONOCLONAL ANTIBODIES
  • TABLE 5 CHIMERIC MONOCLONAL ANTIBODIES
  • TABLE 6 HUMANIZED MONOCLONAL ANTIBODIES
  • TABLE 7 HUMAN MONOCLONAL ANTIBODIES
  • TABLE 8 DIFFERENCES BETWEEN HYBRIDOMA TECHNOLOGY AND RECOMBINANT TECHNOLOGY
  • TABLE 9 COMPARISON OF VARIOUS EXPRESSION SYSTEMS FOR RECOMBINANT PHARMACEUTICAL PROTEINS
  • TABLE 10 MURINE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
  • TABLE 11 CHIMERIC MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
  • TABLE 12 HUMAN MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
  • TABLE 13 HUMANIZED MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
  • TABLE 14 NEW APPROVALS OF MONOCLONAL ANTIBODIES FROM JANUARY 2009 TO MAY 2014
  • TABLE 15 RECALLS FROM JANUARY 2009 TO JUNE 2014
  • TABLE 16 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS FROM JANUARY 2009 TO JANUARY 2014
  • TABLE 17 SAFETY ALERTS FROM 2010 TO MAY 2014
  • TABLE 18 MONOCLONAL ANTIBODIES IN PHASE I CLINICAL TRIALS
  • TABLE 19 MONOCLONAL ANTIBODIES IN PHASE II CLINICAL TRIALS
  • TABLE 20 MONOCLONAL ANTIBODIES IN PHASE III CLINICAL TRIALS
  • TABLE 21 MONOCLONAL ANTIBODIES IN PHASE IV CLINICAL TRIALS
  • TABLE 22 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES FROM 2009 TO JUNE 2014
  • TABLE 23 GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 24 MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013 (%)
  • TABLE 25 GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 26 MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013 (%)
  • TABLE 27 GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 28 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 29 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 30 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 31 GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 32 MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013 (%)
  • TABLE 33 GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, THROUGH 2019 ($ MILLIONS)
  • TABLE 34 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 ($ MILLIONS)
  • TABLE 35 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 ($ MILLIONS)
  • TABLE 36 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2019 ($ MILLIONS)
  • TABLE 37 GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, THROUGH 2019 ($ MILLIONS)
  • TABLE 38 MARKET SHARES FOR ANTIBODY DRUGS BY DISEASES, 2013 (%) 8
  • TABLE 39 VARIOUS TYPES OF AUTOIMMUNE DISEASES
  • TABLE 40 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 41 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 42 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN
  • TABLE 43 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 44 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 45 TYPES OF LYMPHOMAS
  • TABLE 46 TYPES OF LEUKEMIA
  • TABLE 47 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 48 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 49 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 50 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 51 LEADING MANUFACTURERS/SUPPLIERS OF MURINE MONOCLONAL ANTIBODIES, 2013
  • TABLE 52 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013 (%)
  • TABLE 53 LEADING MANUFACTURERS/SUPPLIERS OF CHIMERIC MONOCLONAL ANTIBODIES, 2013
  • TABLE 54 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013 (%)
  • TABLE 55 LEADING MANUFACTURERS/SUPPLIERS OF HUMANIZED MONOCLONAL ANTIBODIES, 2013
  • TABLE 56 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013 (%)
  • TABLE 57 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN MONOCLONAL ANTIBODIES, 2013
  • TABLE 58 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013 (%)
  • TABLE 59 NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014
  • TABLE 60 NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014
  • TABLE 61 NUMBER OF PATENTS BY COMPANY, 2009-JUNE 2014
  • TABLE 62 NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014
  • TABLE 63 PATENT SHARES BY COUNTRY, 2009-JUNE 2014
  • TABLE 64 NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014
  • TABLE 65 NANOBODIES IN DEVELOPMENT

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 1 GLOBAL REVENUE OF ANTIBODY DRUGS BY TYPE, 2012-2019 ($ MILLIONS)
  • FIGURE 2 MARKET SHARE OF ANTIBODY DRUGS BY TYPE, 2013 (%)
  • FIGURE 3 GLOBAL REVENUE OF ANTIBODY DRUGS BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 4 MARKET SHARE OF ANTIBODY DRUGS BY REGION, 2013 (%)
  • FIGURE 5 GLOBAL REVENUE OF MURINE MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 6 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 7 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 8 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 9 GLOBAL REVENUE OF MANUFACTURING PROCESSES BY TYPE OF MONOCLONAL ANTIBODIES, 2012-2019 ($ MILLIONS)
  • FIGURE 10 MARKET SHARE OF ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2013 (%)
  • FIGURE 11 GLOBAL REVENUE OF MURINE ANTIBODY DRUGS BY MANUFACTURING PROCESS, 2012-2019 ($ MILLIONS)
  • FIGURE 12 GLOBAL REVENUE OF CHIMERIC MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 ($ MILLIONS)
  • FIGURE 13 GLOBAL REVENUE OF HUMAN MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 ($ MILLIONS)
  • FIGURE 14 GLOBAL REVENUE OF HUMANIZED MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2012-2019 ($ MILLIONS)
  • FIGURE 15 GLOBAL REVENUE FOR ANTIBODY DRUGS BY DISEASES, 2012-2019 ($ MILLIONS)
  • FIGURE 16 MARKET SHARE FOR ANTIBODY DRUGS BY DISEASES, 2013 (%)
  • FIGURE 17 GLOBAL REVENUE OF ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY TYPE, 2012-2019 ($ MILLIONS)
  • FIGURE 18 GLOBAL MARKET FOR ANTIBODY DRUGS IN AUTOIMMUNE DISEASES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 19 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY TYPE, 2012-2019 ($ MILLIONS)
  • FIGURE 20 GLOBAL REVENUE OF ANTIBODY DRUGS IN SOLID TUMOR BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 21 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY TYPE, 2012-2019 ($ MILLIONS)
  • FIGURE 22 GLOBAL REVENUE OF ANTIBODY DRUGS IN LYMPHOMA AND LEUKEMIA BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 23 GLOBAL REVENUE OF ANTIBODY DRUGS BY APPLICATION IN OTHER DISEASES BY TYPE, 2012-2019 ($ MILLIONS)
  • FIGURE 24 GLOBAL REVENUE OF ANTIBODY DRUGS IN OTHER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 25 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR MURINE MONOCLONAL ANTIBODIES, 2013 (%)
  • FIGURE 26 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR CHIMERIC MONOCLONAL ANTIBODIES, 2013 (%)
  • FIGURE 27 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMANIZED MONOCLONAL ANTIBODIES, 2013 (%)
  • FIGURE 28 MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR HUMAN MONOCLONAL ANTIBODIES, 2013 (%)
  • FIGURE 29 NUMBER OF PATENTS BY YEAR, 2009-JUNE 2014
  • FIGURE 30 NUMBER OF PATENTS BY CATEGORY, 2009-JUNE 2014
  • FIGURE 31 NUMBER OF PATENTS BY COUNTRY, 2009-JUNE 2014 (%) (%)
  • FIGURE 32 NUMBER OF PATENTS BY ASSIGNEE, 2009-JUNE 2014
Back to Top